MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Search

Boston Scientific Corp.

Ouvert

SecteurSoins de santé

88.04 -0.1

Résumé

Variation du prix de l'action

24h

Actuel

Min

88.04

Max

88.04

Chiffres clés

By Trading Economics

Revenu

1.4B

2.2B

Ventes

4M

5.1B

P/E

Moyenne du Secteur

51.187

90.831

BPA

0.75

Marge bénéficiaire

43.87

Employés

53,000

EBITDA

-341M

1B

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+42.82% upside

Dividendes

By Dow Jones

Prochains Résultats

5 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-7.1B

142B

Ouverture précédente

88.14

Clôture précédente

88.04

Sentiment de l'Actualité

By Acuity

61%

39%

298 / 361 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Boston Scientific Corp. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

15 janv. 2026, 13:29 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 janv. 2026, 12:35 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 janv. 2026, 12:29 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

22 oct. 2025, 11:00 UTC

Résultats

Boston Scientific Raises Outlook on Continued Cardiovascular Growth

15 janv. 2026, 14:37 UTC

Actions en Tendance

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 janv. 2026, 13:45 UTC

Acquisitions, Fusions, Rachats

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 janv. 2026, 12:04 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 janv. 2026, 12:03 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 janv. 2026, 12:01 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 janv. 2026, 12:00 UTC

Acquisitions, Fusions, Rachats

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 janv. 2026, 12:00 UTC

Acquisitions, Fusions, Rachats

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

12 janv. 2026, 12:04 UTC

Acquisitions, Fusions, Rachats

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

12 janv. 2026, 12:04 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Specific Terms of Valencia Transaction Not Disclosed >BSX

12 janv. 2026, 12:03 UTC

Acquisitions, Fusions, Rachats

Boston Scientific: Valencia Focused on Development of Solutions to Treat Bladder Dysfunction >BSX

12 janv. 2026, 12:00 UTC

Acquisitions, Fusions, Rachats

Boston Scientific Announces Agreement To Acquire Valencia Technologies Corporation >BSX

18 nov. 2025, 17:06 UTC

Résultats

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18 nov. 2025, 12:01 UTC

Résultats

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

30 oct. 2025, 12:38 UTC

Résultats

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

30 oct. 2025, 12:01 UTC

Résultats

Looking to Diversify Out of the AI Trade? Buy Boston Scientific Stock. -- Barrons.com

22 oct. 2025, 10:32 UTC

Résultats

Boston Scientific Sees 4Q Organic Sales Up 11%-13% >BSX

22 oct. 2025, 10:32 UTC

Résultats

Boston Scientific Sees 4Q Sales Up 14.5-16.5% >BSX

22 oct. 2025, 10:31 UTC

Résultats

Boston Scientific Sees 2025 Organic Sales Up About 15.5% >BSX

22 oct. 2025, 10:31 UTC

Résultats

Boston Scientific Sees 2025 Sales Up About 20% >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees FY Adj EPS $3.02-Adj EPS $3.04 >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q Organic Sales Up 15.3% >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q Adj EPS 75c >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees FY EPS $1.97-EPS $2.01 >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific Sees 4Q EPS 48c-EPS 52c >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q Sales $5.07B >BSX

22 oct. 2025, 10:30 UTC

Résultats

Boston Scientific 3Q EPS 51c >BSX

Comparaison

Variation de prix

Boston Scientific Corp. prévision

Objectif de Prix

By TipRanks

42.82% hausse

Prévisions sur 12 Mois

Moyen 125.78 USD  42.82%

Haut 140 USD

Bas 112 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

20

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

102.95 / 104.93Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

No Evidence

Sentiment

By Acuity

298 / 361Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat